Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

M. Miyan¹, J. Schmidt-Mende²,3, R. Kiessling², I. Poschke⁴† and J. de Boniface¹,5†*

Abstract

Background: Molecular subtypes of breast cancer and presence of tumor-infiltrating immune cells have both been implicated as important predictive and prognostic factors for improved risk stratification and treatment individualization of breast cancer patients. Their association, however, has not been studied in detail. The aim of this study was to evaluate the expression of the T cell markers CD8, FoxP3, CD3 and ζ-chain in molecular subtypes of the invasive margin and tumor center of breast cancer and corresponding sentinel nodes and to deduct prognostic information from these findings.

Methods: Tumor and sentinel node sections from 177 patients with primary, invasive, unilateral early-stage breast cancer were stained by immunohistochemistry and T-cell phenotypes quantified manually. Clinical data were collected from medical records.

Results: The degree of T-cell infiltration and expression of all markers differed significantly among the molecular subtypes, being highest in non-luminal, more aggressive tumors: more T-cell infiltration and higher expression of all markers were associated with hormone receptor negativity, higher proliferation and higher histological grades, but also with larger tumor size. Basal-like tumors, and most remarkably their tumor centers, hosted the highest number of FoxP3+ T-cells with an unfavorable ratio to cytotoxic CD8+ T-cells. T-cell infiltration was generally higher in the invasive margin than the tumor center. A scoring system based on densities of CD3 and CD8 could significantly separate molecular subtypes (p < 0.001).

Conclusions: Thus, immunological patterns with functional implications within each subtype are associated with prognostic factors. These findings should be further validated in studies using larger patient populations and longer follow-up.

Keywords: Breast neoplasms, Cytotoxic T-lymphocytes, Regulatory T-lymphocytes, Tumor-infiltrating lymphocytes, Molecular subtypes

Background

Breast cancer is the most common cancer among women, with an annual incidence of more than 1.6 million cases worldwide which is expected to increase further [1]. The past decades have seen significant improvements in patient survival, likely due to increased awareness, earlier detection through screening programs and advances in treatment [2]. Further improvements are dependent on precise classification for prognostication and prediction, and for the adequate choice of individualized treatment alternatives.

In order to modify and modernize breast cancer classification, Perou et al. [3] proposed five genetically distinct groups based on gene expression microarrays. These ‘molecular subtypes’ have repeatedly been validated since and shown to have accurate prognostic potential...
There are commercially available multigene signature assays for subdivision of tumors into these molecular subtypes, however, estrogen and progesterone hormone receptors, the growth factor receptor Her2/Neu and the proliferation marker Ki-67 are acknowledged as clinical surrogate markers [5]. These possess the advantage of being widely used in routine practice, affordable and available [6].

Apart from the above-mentioned molecular subtypes, immunological tumor-host interactions have received increasing attention as a prognostic and predictive tool [7, 8]. Immune evasion, i.e. the ability of the tumor to avoid or escape detection and elimination by the immune system, has been highlighted as one the emerging hallmarks of cancer, necessary for tumor progression and metastasis [9]. Furthermore, tumors are able to modify anti-tumor immunological reactions, a development known as immunoeediting [10]. Several T-cell phenotypes and functional markers have been investigated as potential prognostic and predictive factors in breast cancer, such as CD8+ T-cells [11, 12], FoxP3 [13, 14] and the ζ-chain of the T-cell receptor (see Additional file 1: Table S1) [15–17].

Based on tumor infiltration by T-cells, at least two prognostic scoring systems with promising clinical potential have been developed this far in other types of cancer. Firstly, Brandwein-Gensler includes the lymphocytic host response (LHR) in a risk model for head and neck squamous cell cancer [18]. This model correlates with disease progression and survival, even after adjustment for clinical confounders, and a higher LHR has been associated with increased time to disease progression. Secondly, the ‘Immunoscore’ assesses the density of CD3+ and CD8+ T-cells in the tumor center (TC) and the invasive margin (IM). It was recently shown to outperform the TNM system’s prognostic power for early-stage colorectal cancer [19, 20].

Conflicting evidence exists regarding the relative importance and significance of different T-cell phenotypes, and it is likely that their importance and predictive capacity varies depending on breast cancer subtype and tumor microenvironment. Therefore, it is of considerable scientific interest to study T-cell infiltration in the context of molecular subtypes.

Methods
A prospective study population of breast cancer patients (n = 43) consecutively operated at the Department of Breast and Endocrine Surgery, Karolinska University Hospital, was enrolled in 2009–2010 for immunological analysis. In order to increase the study population, additional patients were identified from the prospective operation log database during the same time period, operated in a consecutive manner. Thus, the study population consisted of 177 previously untreated patients with primary, unilateral invasive breast cancer without clinical signs of regional or distant metastasis. All patients were scheduled for sentinel lymph node biopsy and received adjuvant treatment according to current treatment protocols.

Clinical parameters, as well as patient and tumor characteristics: i.e. age, tumor size, nodal status, TNM-stage, estrogen and progesterone receptor status, Her2/Neu-status, Ki-67 proliferative index, histological grade, histological subtype, LVI, adjuvant treatment, relapse and mortality was compiled from medical files. For subdivision into intrinsic molecular subtypes, the clinical surrogate parameters of estrogen and progesterone receptor positivity, Her2/Neu-status, and Ki-67 labeling index were applied as described in the St Gallen consensus report from 2013 [5]. Tumors were thus subdivided into the five categories luminal A, luminal B, luminal B/Her2/Neu-overexpressing, non-luminal Her2/Neu-overexpressing and basal-like (triple-negative).

Whole tissue sections of 177 tumors and their corresponding sentinel nodes were retrospectively collected from the Department of Pathology at Karolinska University Hospital for immunological analysis. Before staining, 4 µm thick sections were cut from paraffin-embedded tumor blocks, dewaxed in xylene and rehydrated in decreasing ethanol concentrations, from 100 to 70 %. Pretreatment with citrate buffer (pH 6.0) was performed. Subsequently, samples were heated 10–12 min in a microwave at 750 W up to 98 °C. To facilitate antigen retrieval, samples were further boiled for 20 min at 350 W. Samples were then cooled in a water bath for 20 min. Sections were incubated in 0.5 % H2O2 for 30 min to prevent endogenous peroxidase activity and thereafter washed in water followed by TBS (Triss-Buffer-Saline). After these initial steps, two different protocols ensued for CD3, ζ-chain- and CD8, FoxP3-staining, respectively.

CD3 and ζ-chain-staining
Unspecific binding sites were blocked using 1 % BSA (bovine serum albumin) in TBS for 30 min. Without prior washing, the primary antibody diluted in 1 % BSA was dripped on and the samples were incubated in a refrigerator overnight. For CD3, the primary antibody was rabbit-anti-human, Dako (A0452), 1:800. For the ζ-chain, the primary antibody used was mouse-anti-human, Santa Cruz Biotechnology (sc1239), 1:4 000. The next day, samples were taken out from the refrigerator and washed in TBS 3 × 5 min. A biotinylated secondary antibody (Vector Laboratories, 1:200, goat-anti-rabbit, BA-1000 for CD3 and horse-anti-mouse, BA-2000 for CD3-ζ) in 0.2 % Triton-X in TBS was applied, and sections were incubated for 30 min. Meanwhile, the tertiary
antibody (ABC-Po, PK-6100, Vector Laboratories) was prepared using two units of Avidin, two units of Biotin and 96 units of 0.2 % Triton-X in TBS. The mix was left in room temperature for 30 min. After the secondary antibody had been applied for 30 min, washing in TBS for 3 × 5 min ensued. The tertiary antibody was applied 30 min after being mixed and sections were once again incubated for 30 min, followed by another washing in TBS for 3 × 5 min. Then DAB-kit, SK-4100 (Vector Laboratories) was used in accordance with the manufacturer’s description. Nuclear staining was done using Mayers HTX (Hematoxylin) and sections were washed in lukewarm water. Sections were then dehydrated, and bathed for a few minutes in increasing concentrations of ethanol, from 70 to 100 %. Finally, they were bathed in xylene and mounted on a xylene-based assemblage-material.

FoxP3/CD8
Unspecific binding sites were blocked using 2.5 % horse-serum for 30 min. No washing was performed. Primary antibodies diluted in 1 % BSA [FoxP3: mouse-anti-human, eBioscience (14-4777-82), 1:100 and CD 8: rabbit-anti-human, Spring, SP Clone (M3162), 1:100] were mixed into the solution and incubated overnight in a refrigerator-tempered moisture chamber. The next day, sections were washed in TBS 3 × 5 min. Secondary antibodies [FoxP3: biotinylated horse-anti-mouse, Vector Laboratories (BA-2000) and CD8: ImPress peroxidase, anti-rabbit, Vector Laboratories (MP-7401)] were added and then incubated for 30 min. During the incubation time, the tertiary antibody (ABC-AP, AK 5000, Vector Laboratories) was prepared using one unit of Avidin, one unit of Biotin and 98 units of 0.2 % Triton X in TBS. After the secondary antibody had been applied for 30 min, washing in TBS for 3 × 5 min ensued. The tertiary antibody was applied 30 min after being mixed and sections were once again incubated for 30 min, followed by another washing in TBS for 3 × 5 min. Vector Blue Substrate Kit, Vector Laboratories (SK-5300), was used in accordance with the manufacturer’s instructions, followed by addition of DAB-kit, Vector Laboratories (SK-4100). Nuclear staining was done using Mayers HTX (Hematoxylin) and sections were washed in lukewarm water. Finally, sections were mounted on water-based assemblage material.

Evaluation of occurrence and distribution of CD3, ζ-chain, CD8 and FoxP3
Samples were analyzed by an experienced pathologist together with the student. Patient identification was coded to ensure a blinded assessment. Three areas of interest were selected: the tumor invasive margin, where the front of the tumor cells interact with the surrounding tumor stroma, the tumor center, and the paracortex of the sentinel node. Here, in the main T-cell area of the lymph node, T-cells encounter antigen-presenting cells deriving from the tumor and T-cell activation takes place. The pathologist assessed these three areas of interest in order to identify the high power field (HPF) per area showing the largest amount of T-cells expressing the respective marker for subsequent manual counting. For analysis of the number of cells expressing the marker of interest, both investigators analyzed samples independently of one another. Inter-individual accordance was assessed using approximately 20 samples and deemed to be sufficient, although no statistical analysis was performed to assess a kappa-value. The software ImageJ (http://www.imagej.nih.gov/ij/), which allows the user to mark already counted cells, was used to aid manual cell counting. Cells were counted in the selected HPF with the densest T-cell infiltration of the respective phenotype.

Assessment of lymphocytic host reaction
LHR was investigated in tissue sections using the definitions provided by Brandwein-Gensler et al. [18].

Statistical analysis
All distributions were tested for normality using the Shapiro–Wilks test (if n < 50) or the Kolmogorov–Smirnov test (if n > 50) and parametric or non-parametric tests were used accordingly. The Kruskal–Wallis test was used to assess differences in median expression between more than two groups in order to decrease the probability of type 1-errors. If the significance level was found to be below 0.05, the Mann–Whitney U test was used to test any difference between two separate groups specifically. When different areas were compared within the same individuals, Wilcoxon sum rank test for paired samples was used. Occasionally (when normality could not be rejected), Student’s t test and Levene’s test for equality of variance were used for the same purpose. Chi square cross-tabulation was used to test associations between two ordinal or nominal variables. Fisher’s exact test was used for equivalent purposes when the underlying assumptions of Chi Square cross-tabulation were not fulfilled. Bivariate correlations were tested using Pearson Correlation coefficient or Spearman’s Rank Correlation Coefficient depending on data normality. All statistical analyses were performed using IBM SPSS Statistics, version 22.0 (SPSS Inc., Chicago, Illinois, USA). A two-tailed α < 0.05 was considered statistically significant.

Results
Overall, 177 patients were included. Patient and tumor characteristics are presented in Table 1. Median follow-up time was 47 months (0–58). Seven patients
died, three of whose deaths were due to breast cancer. Recurrence was diagnosed in 12 patients, most commonly (seven patients) at a distant location. Local (within the same breast) and axillary recurrence occurred in three patients, respectively. One patient had both axillary and distant recurrences. Due to the low number of events, we do not report on survival analyses; these were performed but shown to not render significance even for established clinical prognostic factors, confirming the unfeasibility of survival analysis in this cohort thus far.

Lymphocytic host response correlates positively with immunological markers and is associated with poor prognostic factors

Lymphocytic host response (LHR), categorized into four groups (negative, weak, moderate and strong) according to the original description [18], correlated positively with the density of all measured immunological markers (Spearman’s Rho 0.368–0.799, each p < 0.01). Tumors displaying higher degrees of LHR had significantly higher histological grades (p = 0.003) and proliferation (p < 0.001), and were negative for ER and PR (p < 0.001). LHR showed no relation to other clinical parameters.

The five intrinsic molecular subtypes (luminal A, luminal B, luminal B Her2/Neu overexpressing, non-luminal Her2/Neu overexpressing and basal-like) differed considerably in their respective LHR (p < 0.001). While the luminal (ER-positive) subtypes generally exhibited a negative or weak LHR, the non-luminal (ER-negative) ones displayed a strong or moderate LHR, as depicted in Fig. 1. In particular, large discrepancies were found for the luminal A subtype against the non-luminal subtypes (p < 0.001).

The density of T-cell phenotypes differs between tumor areas

To better characterize the immune infiltrate, we performed immunohistochemistry for total T-cells (CD3), cytotoxic T-cells (CD8), regulatory T-cells (FoxP3) and T-cell functionality (CD3-zeta-chain, see Additional file 1: Table S1 for a description of the investigated markers). Representative images for CD8 and FoxP3 are presented in Fig. 2. For all T-cell phenotypes, the mean number of infiltrating cells per high power field (HPF) was significantly higher in the invasive margin (CD3: 306.93 ± 203.32; CD8: 149.37 ± 108.68; FoxP3: 20.26 ± 26.72; CD3-zeta: 98.93 ± 103.09) than in the tumor center (CD3: 126.81 ± 119.35; CD8: 82.84 ± 83.86; FoxP3: 14.90 ± 25.47; CD3-zeta: 31.11 ± 52.32; p < 0.0001). The numbers of positive T-cells in the IM correlated positively with their TC equivalents for all markers (each p < 0.001, Spearman’s Rho 0.415–0.752). Not surprisingly, densities of

### Table 1 Patient and tumor characteristics

| Characteristic | N (%) |
|----------------|-------|
| Age at operation (years) | 62 (32–91) |
| Tumor size (mm) | 17.5 (5–100) |
| Nodal status | |
| N0 | 124 (70.1) |
| N1–3 | 53 (29.9) |
| TNM-stage | |
| I | 85 (48.0) |
| II | 80 (45.2) |
| III | 12 (6.8) |
| Estrogen receptor status | |
| Negative | 26 (14.7) |
| Positive | 151 (85.3) |
| Progesterone receptor status | |
| Negative | 47 (26.6) |
| Positive | 130 (73.4) |
| Her2/Neu status (FISH) | |
| Negative | 154 (87.0) |
| Positive | 23 (13.0) |
| Ki-67 (%) | 18 (1-95) |
| Low-proliferative | 94 (53.1) |
| High-proliferative | 82 (46.3) |
| Nottingham histological grade | |
| I | 38 (21.5) |
| II | 84 (47.5) |
| III | 55 (31.1) |
| Molecular subtype | |
| Luminal A | 88 (49.7) |
| Luminal B | 46 (26.0) |
| Luminal B Her2/Neu-overexpressing | 17 (9.6) |
| Non-luminal Her2/Neu-overexpressing | 6 (3.4) |
| Basal-like | 20 (11.3) |
| Lymphovascular invasion (LVI) | |
| Yes | 24 (13.6) |
| No | 133 (75.1) |
| Adjuvant radiotherapy | |
| Breast or chest wall only | 110 (62.2) |
| Locoregional | 33 (18.6) |
| Adjuvant chemotherapy | |
| Anthracyclines | 53 (29.9) |
| Taxane-based | 30 (16.9) |
| Other | 1 (0.0) |
| Adjuvant endocrine therapy | 151 (85.3) |
| Anti-Her2/Neu therapy (trastuzumab) | 19 (10.7) |

Figures are N and (%) unless otherwise stated

* a Median (range)

b The cut-off value being 20 %
all analyzed T-cell phenotypes (apart from CD-zeta the density of which was not analyzed in the SLN) were highest in the SLN (CD3: 1528.63 ± 485.81; CD8: 344.14 ± 199.60; FoxP3: 71.66 ± 82.50). In 12 cases, an additional non-sentinel lymph node could be evaluated, but the densities of T-cell phenotypes did not differ from the SLN itself.

### Density of T-cell phenotypes differs significantly in different molecular subtypes

Overall, all studied T-cell phenotypes differed significantly between molecular subtypes, both in the invasive margin (CD3: p = 0.013; CD8: p < 0.001; FoxP3: p < 0.001 and CD3-ζ: p < 0.007) and the tumor center (CD3: p = 0.001; CD8: p = 0.042; FoxP3: p < 0.001 and CD3-ζ: p = 0.002). The density of all T-cell phenotypes in both invasive margin and tumor center was consistently lowest in the luminal A subtype. Interestingly, the more aggressive subtypes each had a distinct profile, with basal-like tumors showing the highest FoxP3 and CD8 densities, Her2/neu overexpressing tumors the highest CD3-ζ density and luminal B Her2/neu positive tumors the highest CD3 density in the invasive margin and CD8 levels similar to basal-like tumors. All 19 basal-like tumors had some degree of FoxP3 positivity while 29 of 81 (36%) luminal A-tumors were entirely negative for...
FoxP3. Figure 3 shows numbers of positive T-cells for each marker per subtype and tumor area, highlighting significant differences between subtypes with the luminal A category as reference group.

A common clinical classification is to separate luminal (ER-positive) tumors from non-luminal ones (ER-negative). Comparing these two groups, all densities of T-cell phenotypes were significantly higher in the non-luminal subtypes ($p < 0.001$) apart from CD8 density in the tumor center.

The number of T-cell phenotypes in the SLN and non-SLNs was not significantly different when comparing molecular subtypes or luminal versus non-luminal tumors.

**T-cell functionality differs among subtypes**

In order to assess the functionality of the T-cells within different subtypes, the number of ζ-chain+ T-cells in relation to CD3+ T-cells was calculated as a ratio. Interestingly, this ratio did not differ significantly between the different subtypes, however, when comparing luminal versus non-luminal tumors, the latter has a significantly lower ratio in the tumor center ($p = 0.012$) but a higher ratio in the invasive margin ($p = 0.022$). The ζ-chain/CD3-ratio positively correlated with LHR (Spearman’s Rho 0.581, $p < 0.01$).

The suppressive versus cytotoxic equilibrium was analyzed using a ratio of FoxP3+ to CD8+, which differed significantly when comparing all subtypes in both invasive margin and tumor center ($p = 0.003$). This ratio was consistently lower in the invasive margin than in the tumor center. The highest ratio was found in basal-like tumors (tumor center $0.62 \pm 0.64$ and invasive margin $0.19 \pm 0.15$) and the lowest in luminal A tumors (tumor center $0.15 \pm 0.29$ and invasive margin $0.09 \pm 0.12$). Here, too, the luminal tumors generally had lower ratios than their non-luminal counterparts, especially in the tumor center ($p < 0.001$). Finally, the cytotoxic potential of the T-cells was assessed by creating a ratio of CD8+ to CD3+ T-cells. This ratio did not differ significantly between subtypes. No differences between subtypes were found in SLNs.

**T-cell phenotypes in the tumor and molecular subtypes are related to established clinical parameters**

Higher densities of T-cell phenotypes were invariably associated with negative prognostic factors as measured by routine histopathological assessment. This held true for all markers with significances listed in Table 2. Interestingly, a higher density of CD8+ and CD3+ T-cells in the paracortex of the SLN was associated with the debated prognostic factor of lymphovascular tumor invasion (LVI). A higher ζ-chain/CD3 ratio was associated with ER ($p = 0.022$ and 0.012 for invasive margin and tumor center), PR negativity ($p = 0.003$ for tumor center), and ductal tumor histology. While the CD8/CD3 ratio was higher in the SLN of younger individuals, it was also higher in the tumor center of patients 50 years of age or older. A higher
FoxP3/CD8 ratio was significantly associated with ER negativity ($p = 0.031$ and $< 0.001$ for invasive margin and tumor center), high proliferation (both areas $p < 0.001$) and tumor histological grade ($p = 0.013$ and $0.034$, respectively).

Molecular subtypes were confirmed to be related to established clinical parameters: while 40% of all basal-like tumors affected patients below the age of 50, all tumors of the luminal B Her2/Neu-positive subtype were found in patients above 50 years of age. Luminal A tumors also predominantly affected the older age group, in 83.9% of cases. Non-luminal tumors were associated with higher histological grades. Lymphovascular invasion (LVI) was most commonly observed in the luminal B Her2/Neu-positive subtype (35.7%), and most infrequently in luminal A tumors (7.7%). No significant association, however, was found regarding tumor size, nodal status, TNM stage or disease relapse.

### Table 2 Density of T-cell phenotypes in relation to established prognostic markers

|                      | CD8    | FoxP3  | ζ-chain | CD3    |
|----------------------|--------|--------|---------|--------|
| **Invasive margin**  |        |        |         |        |
| Age at operation (<50 vs ≥50 years) | n.s.   | n.s.   | n.s.    | n.s.   |
| Tumor size (T1 vs T2 vs T3)        | n.s.   | n.s.   | n.s.    | n.s.   |
| Nodal status (N0 vs N1)            | n.s.   | n.s.   | n.s.    | n.s.   |
| Tumor stage (TNM)                 | n.s.   | n.s.   | n.s.    | n.s.   |
| Estrogen receptor status (pos. vs neg.) | p = 0.001 | p = 0.001 | p = 0.001 | p = 0.027 |
| Progesterone receptor status (pos. vs neg.) | p = 0.004 | p = 0.044 | p = 0.001 | p = 0.002 |
| Her2/Neu status (FISH) (amplified/not amplified) | p = 0.038 | p = 0.039 | p = 0.027 |
| Proliferation (Ki-67) (high vs low) | p = 0.001 | p < 0.001 | p = 0.024 | p = 0.027 |
| Nottingham histological grade     | p < 0.001 | p < 0.001 | p = 0.051 | p = 0.030 |
| Histological subtype (ductal vs lobular) | n.s.   | n.s.   | p = 0.030 | n.s.   |
| Lymphovascular invasion (pos. vs neg.) | n.s.   | n.s.   | n.s.    | n.s.   |
| **Tumor center**                 |        |        |         |        |
| Age at operation (<50 vs ≥50 years) | n.s.   | n.s.   | n.s.    | p < 0.001 |
| Tumor size (T1 vs T2 vs T3)        | p = 0.009 | n.s.   | n.s.    | p = 0.001 |
| Nodal status (N0 vs N1)            | n.s.   | n.s.   | n.s.    | n.s.   |
| Tumor stage (TNM)                 | p = 0.010 | p = 0.050 | n.s.    | p = 0.001 |
| Estrogen receptor status (pos. vs neg.) | p = 0.001 | p < 0.001 | p < 0.001 | p < 0.001 |
| Progesterone receptor status (pos. vs neg.) | p = 0.001 | p = 0.009 | p < 0.001 | p = 0.001 |
| Her2/Neu status (FISH) (amplified/not amplified) | n.s.   | n.s.   | p = 0.040 |
| Proliferation (Ki-67) (high vs low) | p = 0.045 | p < 0.001 | p < 0.001 | p < 0.001 |
| Nottingham histological grade     | p = 0.002 | p = 0.005 | p = 0.009 | p = 0.001 |
| Histological subtype (ductal vs lobular) | n.s.   | n.s.   | n.s.    | n.s.   |
| Lymphovascular invasion (pos. vs neg.) | n.s.   | n.s.   | n.s.    | n.s.   |
| **Sentinel node paracortex**      |        |        |         |        |
| Age at operation (<50 vs ≥50 years) | p < 0.001 | n.s.   | n.s.    | n.s.   |
| Tumor size (T1 vs T2 vs T3)        | n.s.   | n.s.   | n.s.    | n.s.   |
| Nodal status (N0 vs N1)            | n.s.   | n.s.   | n.s.    | n.s.   |
| Tumor stage (TNM)                 | n.s.   | n.s.   | n.s.    | n.s.   |
| Estrogen receptor status (pos. vs neg.) | n.s.   | n.s.   | n.s.    | n.s.   |
| Progesterone receptor status (pos. vs neg.) | n.s.   | n.s.   | n.s.    | n.s.   |
| Her2/Neu status (FISH) (amplified/not amplified) | p = 0.022 | n.s.   | n.s.    | n.s.   |
| Proliferation (Ki-67) (high vs low) | p = 0.021 | n.s.   | n.s.    | n.s.   |
| Nottingham histological grade     | n.s.   | n.s.   | n.s.    | n.s.   |
| Histological subtype (ductal vs lobular) | n.s.   | n.s.   | n.s.    | n.s.   |
| Lymphovascular invasion (pos. vs neg.) | p = 0.032 | n.s.   | n.s.    | p = 0.006 |

*Significant values always represent a higher T-cell infiltration for any negative prognostic group.*
An immunological score based on CD3 and CD8 separates molecular subtypes

In order to develop a scoring system based on immunological markers that could accurately separate the molecular subtypes from one another, the density of CD8+ and CD3+ T-cells in both tumor areas was compounded and categorized as either high or low. Samples were excluded if the value of either CD8 or CD3 was missing. Samples were divided into three groups: score I, with tumors exhibiting low density of both markers; score II, tumors displaying high density of either marker (in CD3↑ but CD8↓ cases most likely CD4-dominated tumors) and score III, tumors with high density of both T-cell phenotypes. CD3 and CD8 were selected in accordance with the immunological score for colorectal cancer described earlier [20].

In total, 125 samples could be assessed. Tumors displayed substantially different immunological scores among the molecular subtypes (p < 0.001), with basal-like tumors predominantly showing a high, and luminal A tumors a low score. Figure 4 illustrates the percentage of tumors within each immunological score for each molecular subtype.

Discussion

This report describes differential densities of T-cells expressing the markers CD8, FoxP3, ζ-chain and CD3 in different molecular subtypes of breast cancer and their sentinel lymph nodes. We have here shown that molecular subtypes exhibit different densities of all analyzed T-cell phenotypes and that higher densities are associated with more aggressive tumor subtypes. We could further show that an immunological score based on CD3+ and CD8+ T-cells markedly differed between tumor subtypes.

The presence of tumor-infiltrating lymphocytes has repeatedly been shown to correlate with breast cancer prognosis and treatment response [11–16]. One of the here applied parameters, the lymphocytic host response (LHR) as described by Brandwein-Gensler [18], takes all lymphocytes into account and is based on routine hematoxylin-eosin staining, while all other parameters are specific T-cell markers detected by immunohistochemistry. Interestingly, the overall lymphocytic response yielded very similar results to the more sophisticated immunohistochemical analysis, despite the notion of functional heterogeneity in tumor-infiltrating lymphocytes: no marker had any superior or inferior capacity to illustrate differences among subtypes. Even though we could show that expression of FoxP3 seems to be a specific feature of basal-like tumors, our results suggest that the overall T-cell infiltration, rather than infiltration of specific phenotypes, separates the molecular subtypes. Luminal (ER+) subtypes were denoted by a low immunological response while non-luminal (ER−) subtypes showed clear signs of an immunological host response. The luminal A subtype in particular distinguished itself with a low immunological response: only 2.4 % of all luminal A tumors had a strong LHR, in contrast to 41.7 % of the non-luminal subtypes. These findings are in support of several reports of non-luminal tumors generally exhibiting a higher degree of tumor-infiltration by lymphocytes [21, 22], even though there are contrary results, too [23].

The interesting question is why differential immune infiltration should occur in breast cancer, and how it is associated with prognosis. It seems feasible to assume that the infiltration of immune cells should reflect underlying biological properties of the tumor [20]. Differential gene expression, on which the distinction of molecular

![Fig. 4 Distributions of immunological scores within each subtype. Numbers represent the percentage of each score (I–III) within each molecular subtype](image-url)
subtypes is based, may cause differences in vascularization, lymphatic vessel density, antigenicity, chemokine milieu or cytokines. The occurrence of high endothelial venules, for example, is associated with lymphocytic infiltration and corresponds to a more favorable prognosis in breast cancer; however, an association with molecular subtypes has not yet been explored [24]. Cytotoxic T-cell responses are increasingly found to be directed against mutated epitopes predicted to be immunogenic, and are associated with better patient survival [25]. These inherent distinctions may explain why the subtypes, originally defined by dissimilar gene expression, exhibit inherently differential densities of T-cells. We have previously shown that signs of immunological dysfunction can be detected in the tumor, and even in peripheral blood, of patients with early-stage disease and limited tumor burden [17, 26]. While it became aggravated with tumor progression, these studies suggest that the immune environment is shaped relatively early during breast cancer development.

Interestingly, subtypes associated with a poor prognosis generally had higher numbers of each T-cell phenotype, including those phenotypes that should imply a favorable prognosis, such as CD8+ cytotoxic T cells. While it seems somewhat counter-intuitive at first glance, the higher degree of lymphocytic response, however, predicts an improved response to both adjuvant and neoadjuvant treatment [7, 14, 27]. Consequently, each tumor subtype probably has an inherent degree of infiltration of T-cells, and any prognostic deductions should therefore be done with these inherent differences in mind. Especially in basal-like and Her2/Neu-overexpressing breast cancer, it has been suggested that a subdivision in tumors with high and low levels of tumor-infiltrating lymphocytes should be attempted for potentially adoptive treatment [28].

In addition, our results suggest that some subtypes might be more likely to respond to immunotherapeutic approaches than others. For example, a first clinical trial targeting the checkpoint inhibitory molecule PD1 showed promising results in patients with metastatic triple-negative tumors [29]. In our study the related basal-like subtype had the strongest degree of immune infiltration, in agreement with studies showing that basal-like tumors are the subtype most frequently exhibiting PD-L1-positive tumor cells as well as immune infiltrate, which correlated with T-cell infiltration and a better prognosis [30]. Of note, some studies found PD-L1 to correlate with poor survival [31]. This likely reflects omission of subtype-specific analysis and/or failure to detect PD-L1 expression, which is IFNγ dependent, in poorly infiltrated subtypes. Such discrepancies illustrate the importance of taking into account the differential immune infiltration patterns within the cancer subtypes.

Another important finding is the fact that all tumor subtypes generally exhibited a more pronounced infiltration in the invasive margin than in the tumor center. This is in agreement with findings from other tumor entities that show that it can be difficult for T-cells to infiltrate into tumors, especially those with a large stromal component, due to physical barriers or the hostile tumor microenvironment [32]. Interestingly, high T-cell densities in both the invasive margin and the tumor center predict better survival in colorectal cancer patients, where a ‘tumor-observing’ immune response around the invasive margin is commonly found [33]. Importantly, we also observed a difference in the proportion of immune cells present at different sites: all tumor types showed a higher ratio of FoxP3+ cells to CD8+ cells in the tumor center, which is coherent with reports showing that tumors can recruit regulatory T-cells as part of their immune escape mechanism, and that these are better adapted to the tumor microenvironment, as they for example are more resistant to reactive oxygen [34, 35]. This would also be in line with the decreased detection of the CD3-zeta chain in the tumor center, as this molecule is known to be down-regulated under conditions of oxidative stress.

To the best of our knowledge, no study has yet evaluated the relationship between T-cell densities in breast cancer sentinel lymph nodes and molecular subtypes. Compared to our observations in tumor tissue, sentinel lymph node analysis yielded far fewer inter-subtype differences. Our study population, however, consisted of clinically node-negative patients, and in 70% of patients, node negativity was confirmed by histopathology. Some other studies have seen associations between increased FoxP3 expression in sentinel nodes and nodal metastasis [36], while others did not [37]. Considering that different subtypes have different propensities of developing nodal metastasis [38], differential FoxP3 expression could possibly have been detected had the study included later-stage patients. The only marker which differed significantly among molecular subtypes in the sentinel node was CD8, with higher densities being seen in the luminal B Her2 positive-subtype compared to luminal A tumors. This may reflect the general immunogenicity of this tumor subtype, as luminal B Her2 tumors also had the highest number of tumor-infiltrating CD8+ T-cells. Similarly, this subtype had the highest degree of LVI, which may explain the association with CD8+ accumulation in the sentinel node.

The immunoscore developed for colorectal cancer predicts relapses among early-stage tumors more accurately than classical TNM staging and consequently bears therapeutic implications; patients at high risk could potentially benefit from adjuvant treatment not normally given in early-stage disease [19, 20]. De Kruijf et al. [39] used a panel
of immunological markers to construct seven immune subtypes in early breast cancer based on biological rationale. After an initial training set, these immune subtypes differed significantly in a multivariate analysis for relapse-free time in an independent validation set. These results indicate that using immunological markers for risk stratification purposes has potential also in the setting of breast cancer. Analogously, we have here shown that a scoring system based on densities of CD3+ and CD8+ T-cells significantly distinguishes molecular subtypes. Since the subtypes predict prognosis, and densities of immunological markers are known to do likewise, further research should compare long-term survival and relapse data among these different immunological scores, potentially separating high-risk patients within each subtype.

Conclusions
Molecular subtypes of breast cancer exhibit differential tumoral densities of CD8+, FoxP3+, ζ-chain+ and CD3+ T-cells. Large variations were observed within each tumor subtype, especially in quantity, rather than functionality of T-cells. This may have prognostic implications but needs to be validated using a larger patient population with longer follow-up time.

Additional file

Additional file 1: Table S1. Phenotypic and functional markers used for analysis of T-cell infiltrates.

Abbreviations
CD: cluster of differentiation; ER: estrogen receptor; FISH: fluorescent in situ hybridization; FoxP3: forkhead box P3; Her2/neu: human epidermal growth factor receptor-2; HPF: high-power field; IM: invasive margin; LHR: lymphocytic host response; LVI: lymphovascular invasion; PR: progesterone receptor; TIL: tumor-infiltrating lymphocytes; TC: Tumor Center; TNM: tumor, node, metastasis.

Authors’ contributions
JB designed, managed and carried out the study, performed data analysis and interpretation and drafted the manuscript. MM carried out the data collection, participated in the assessment of immunohistochemical stainings and data analysis and drafted the manuscript. JSM carried out the assessment of immunohistochemical stainings. RK participated in the study design and management. IP participated in the design of the study, in statistical analyses and data interpretation and contributed in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We are deeply grateful for the technical support from Inger Bodin, who performed all immunohistochemical staining, and Hans Pettersson, for statistical review and advice.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All material and data are stored at Karolinska University Hospital, Stockholm, Sweden, and may be shared upon request directed to the corresponding author.

Consent for publication
No individual data are presented in this manuscript.

Ethics approval and consent to participate
All patients gave their general written consent for surgical samples to be stored and used in the local tissue biobank. This retrospective study was approved by the regional ethics committee in Stockholm with diary number 2012/90-31/2 and conducted in accordance with the declaration of Helsinki.

Funding
This study was supported by grants to the senior author from the Swedish Society for Medical Research and the Olle Engkvist Foundation.

Trial registration number
As this study was conducted retrospectively on routinely and prospectively collected biobank material and data from breast cancer registries, no trial registration number was obtained.

Received: 25 August 2015 Accepted: 18 July 2016
Published online: 29 July 2016

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebello M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Cancer intervention and surveillance modeling network (CISNET) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.
3. Pernou CM, Sorlie T, Ezen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
4. Norum JH, Andersen K, Sorlie T. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. Br J Surg. 2014;101:925–38.
5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Procter M, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.
6. Viale G. The current state of breast cancer classification. Ann Oncol. 2012;23(Suppl 10):x207–10.
7. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kurz G, Nekludova V, Schnader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial. PLoS ONE. 2013;8:e79775.
8. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sauver-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
10. Kim R, Emi M, Tanabe K. Cancer immuneediting from immune surveillance to immune escape. Immunology. 2007;121:1–14.
11. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55.
12. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.
13. Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor
receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16:432.

14. Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, et al. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat. 2015;149:587–96.

15. Kuhn MJS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006;24:133–9.

16. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother. 2004;53:865–78.

17. De Bonface J, Poschke I, Mao Y, Kiesling R. Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer. 2011;131(1):129–39.

18. Brandwein-Gensler M, Smith RV, Wang B, Penner C, Theilken A, Broughel D, et al. Validation of the histologic risk model in a new cohort of patients with head and neck squamous cell carcinoma. Am J Surg Path. 2010;34:676–88.

19. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molrid R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.

20. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscope: a worldwide task force. J Transl Med. 2012;10:205.

21. Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer. 1990;62:971–5.

22. Tsang JY, Ni YB, Chan SK, Yamaguchi R, Tanaka M, Tan PH, et al. Increased lymphocytic infiltration in breast cancer correlates with molecular subtypes and HER2 gene amplification. Histopathology. 2013;62:963–5.

23. Dong DD, Yie SM, Li K, Li F, Xu Y, Xu G, et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol. 2012;73:998–1004.

24. Martinet L, Garrido J, Girard JP. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology. 2012;1:789–90.

25. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743–50.

26. Poschke I, De Bonface J, Mao Y, Kiesling R. Tumor-induced changes in the phenotype of blood-borne and tumor-associated T cells of early stage breast cancer patients. Int J Cancer. 2012;131(7):1611–20.

27. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544–50.

28. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2:e24720.

29. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase II KEYNOTE-012 Study. J Clin Oncol. 2016;[Epub ahead of print].

30. Sabatier R, Finetti P, Mlamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6(7):5449–64.

31. Guo Y, Yu P, Liu Z, Maimaiti Y, Wang S, Yin X, et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis. PLoS ONE. 2016;11(5):e0156323.

32. Hertmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E. Prevaling role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res. 2014;20(13):3422–33.

33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.

34. Mougiakakos D, Johannson CC, Kiesling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood. 2009;113(15):3542–5.

35. Mougiakakos D, Johannsson CC, Itschin R, Rotcher M, Kiesling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood. 2011;117(3):857–61.

36. Nakamura R, Sakakibara M, Nagashima T, Sangai T, Arai M, Fujimori T, et al. Accumulation of regulatory T cells in sentinel lymph node is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer. 2009;45:2123–31.

37. Gupta R, Babb JS, Singh B, Chiriboga L, Liebes L, Adams S, et al. The numbers of FoxP3 + lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest. 2011;29:419–25.

38. Voduc KD, Cheang MC, Tyldeley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.

39. de Krijff EM, Engels CC, van de Water W, Bastiaannet E, Smit VT, van de Velde CJ, et al. Tumor immune subtypes distinguish tumor subclones with clinical implications in breast cancer patients. Breast Cancer Res Treat. 2013;142:355–64.